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IMPORTANCE New data and therapeutic options warrant updated recommendations for the
use of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults.
OBJECTIVE To provide updated recommendations for the use of antiretroviral therapy in
adults (aged18 years) with established HIV infection, including when to start treatment,
initial regimens, and changing regimens, along with recommendations for using ARVs for
preventing HIV among those at risk, including preexposure and postexposure prophylaxis.
EVIDENCE REVIEW Apanel of experts in HIV research and patient care convened by the
International Antiviral Society–USA reviewed data published in peer-reviewed journals,
presented by regulatory agencies, or presented as conference abstracts at peer-reviewed
scientific conferences since the 2014 report, for new data or evidence that would change
previous recommendations or their ratings. Comprehensive literature searcheswere conducted
in the PubMed and EMBASE databases through April 2016. Recommendationswere by
consensus, and each recommendationwas rated by strength and quality of the evidence.
FINDINGS Newer data support the widely accepted recommendation that antiretroviral
therapy should be started in all individuals with HIV infection with detectable viremia
regardless of CD4 cell count. Recommended optimal initial regimens for most patients are 2
nucleoside reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor
(InSTI). Other effective regimens include nonnucleoside reverse transcriptase inhibitors or
boosted protease inhibitors with 2 NRTIs. Recommendations for special populations and in
the settings of opportunistic infections and concomitant conditions are provided. Reasons for
switching therapy include convenience, tolerability, simplification, anticipation of potential
new drug interactions, pregnancy or plans for pregnancy, elimination of food restrictions,
virologic failure, or drug toxicities. Laboratory assessments are recommended before
treatment, andmonitoring during treatment is recommended to assess response, adverse
effects, and adherence. Approaches are recommended to improve linkage to and retention in
care are provided. Daily tenofovir disoproxil fumarate/emtricitabine is recommended for use
as preexposure prophylaxis to prevent HIV infection in persons at high risk. When indicated,
postexposure prophylaxis should be started as soon as possible after exposure.
CONCLUSIONS AND RELEVANCE Antiretroviral agents remain the cornerstone of HIV treatment
and prevention. All HIV-infected individuals with detectable plasma virus should receive
treatmentwith recommended initial regimens consisting of an InSTI plus 2 NRTIs. Preexposure
prophylaxis should be considered as part of anHIV prevention strategy for at-risk individuals.
When used effectively, currently available ARVs can sustain HIV suppression and can prevent
newHIV infection.With these treatment regimens, survival rates amongHIV-infected adults
who are retained in care can approach those of uninfected adults.
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T here have been substantial advances in the use of antiret-roviraldrugs(ARVs) for thetreatmentandpreventionofHIVinfection since the last version of these recommendations
in 2014,1 warranting an update to the recommendations.
With rare exception, all HIV-infected individuals with detect-
able viremia, regardless of their CD4 cell count, should begin anti-
retroviral therapy (ART) as soon as possible after diagnosis to pre-
vent disease progression, improve clinical outcomes, and limit
transmission. This recommendation is strongly supported by
recent large randomized clinical trials.2,3 New drugs that combine
excellent potency with greater convenience, safety, and tolerability
make lifelong viral suppression achievable and reduce the risk of
viral resistance. In HIV-infected persons, ART is effective in pre-
venting HIV transmission1,4,5 and provides individual and public
health benefits. Antiretroviral therapy for individuals at risk of
acquiring HIV infection (as postexposure prophylaxis [PEP] or pre-
exposure prophylaxis [PrEP]) prevents HIV acquisition.
This revision of the recommendations discusses the latest de-
velopments inusesofARVs, summarizingcurrentknowledgeonthe
following: when to start therapy, including optimal initial treat-
ment regimens;ART forpatientswithopportunistic infections (OIs);
when and how to switch ART; laboratory monitoring; engagement
in care and ART adherence; and prevention of HIV infection.
Methods
Recommendationswere developed by an international panel of 14
volunteerexperts inHIV researchandpatient careappointedby the
International Antiviral Society–USA. Potential members were
screened forexpertise in the field, involvement in researchandcare,
financial relationships with commercial companies, and ability to
work toward consensus. Thepanel convened inpersonandby con-
ference calls from late 2015 tomid-2016. Teams for eachmajor sec-
tion,eachwitha leadwriter,evaluatedrelevantevidenceanddrafted
recommendations for full panel review.
Evidence used was published in the scientific literature, pre-
sented atmajor scientific conferences, or released as safety reports
by regulatory agencies or data and safety monitoring boards
since 2014.1 Literature searches in PubMed and EMBASE were
designed by an expert in systematic reviews to capture publica-
tions relevant to ART in HIV infection since the 2014 iteration of the
recommendations1 through April 2016. New evidence was consid-
ered in conjunction with evidence used for prior reports.1 Approxi-
mately 320 relevant citations were identified by 1 author (P.V.)
from an initial list of more than 3200. Relevant abstracts publicly
presented at scientific conferences since June 2014were identified
by panel members. Manufacturers of ARVs provided lists of rel-
evant scientific publications or abstracts presented at peer-
reviewed conferences.
These recommendations are focused on adults (defined as
aged18 years) with or at risk of HIV infection in settings in which
most ARVs are available (approved by regulatory bodies or
in expanded access) or in late-stage development (new drug appli-
cation filed). Recommendations were made by consensus
and rated according to the strength of the recommendation and
the quality of the evidence (Table 1). Recommendations that have
not changed substantially or for which few relevant data have
become available since 2014 are included in the 2014 treatment
recommendations1 along with detailed discussion and citations.
Where appropriate, prior citations were included. Further details
about the recommendations development process, panel selec-
tion, summary of evidence collection and literature search strate-
gies, and the sponsor (International Antiviral Society–USA) and its
policies are available in the Supplement.
When to Start
Initiation of Therapy
Recommendations for when to start ART are summarized in Box
1. ART is recommended for all HIV-infected patients with detect-
able viremia, regardless of CD4 cell count (evidence rating AIa).
Randomized clinical trial data now further confirm previous rec-
ommendations for early initiation of ART in adults1,7 because of
the individual-level clinical benefit (reduction in AIDS-related
events, non–AIDS-related events, and all-cause mortality)
(Table 2)2,3,8 and a decreased risk of HIV transmission.4
Patients should understand the goals of treatment andbewill-
ing to initiate therapy. Baseline resistance testing is recommended
for all patients, but initiating therapy prior to availability of the re-
sults may be appropriate in some cases. Recent data suggest little
transmitted drug resistance to integrase strand transfer inhibitors
(InSTIs) and protease inhibitors (PIs) but not nonnucleoside re-
verse transcriptase inhibitors (NNRTIs).9-11
Current Investigational Approaches to Starting Therapy
Initiation of ART is recommended as soon as possible in the setting
of acute HIV infection (evidence rating BIII).1 Initiation prior to the
development of HIV antibody positivity reduces the size of the
latent HIV reservoir, reduces immune activation, and may protect
against infection of central memory T cells. Benefits are maximal
during the first few weeks after HIV infection but are apparent up
Table 1. Strength of Recommendation andQuality of Evidence
Rating Scalea
Rating Definition
Strength of
recommendation
A Strong support for the recommendation
B Moderate support for the recommendation
C Limited support for the recommendation
Quality of
evidence
Ia Evidence from ≥1 randomized clinical trials published
in the peer-reviewed literature
Ib Evidence from ≥1 randomized clinical trials presented
in abstract form at peer-reviewed scientific meetings
IIa Evidence from nonrandomized clinical trials
or cohort or case-control studies published
in the peer-reviewed literature
IIb Evidence from nonrandomized clinical trials or cohort
or case-control studies presented in abstract form
at peer-reviewed scientific meetings
III Recommendation based on the panel’s analysis
of the accumulated available evidence
a Adapted in part from the Canadian Task Force on Periodic Health
Examination.6
Clinical Review & Education Special Communication 2016 Recommendations for Use of ARVs to Treat and Prevent Adult HIV Infection
192 JAMA July 12, 2016 Volume 316, Number 2 (Reprinted) jama.com
Downloaded From: http://jamanetwork.com/ by a UZH Hauptbibliothek / Zentralbibliothek Zuerich User  on 10/21/2016
Copyright 2016 American Medical Association. All rights reserved.
to the first 6 months after infection.12-16 However, early therapy
does not prevent the establishment of the latent HIV reservoir.
Planned discontinuation of early ART after a specific duration of
treatment is not recommended outside research settings; the ben-
efits do not persist and the subsequent viral rebound is associated
with increased clinical events and the potential for transmission
(evidence rating AIa).16-18
Initiation of ART on the same day as diagnosis of HIV infection
has been implemented in several cities.19,20 Evaluation of the long-
term effectiveness and limitations of this strategy is needed.
Initiation of ART in “elite controllers” (defined as patients
with confirmed HIV infection and persistent undetectable HIV
RNA without ART) remains controversial. Elite controllers may
still benefit from ART because they have higher levels of immune
activation and an increased risk of cardiovascular disease and hos-
pitalization compared with individuals achieving virologic sup-
pression with ART.21 Initiation of treatment, however, is recom-
mended for infected persons who have persistent undetectable
viral load without ART but have declining CD4 cell counts (evi-
dence rating BIII).
Recommended Initial Regimens
Recommendations for initial antiretroviral regimens are summa-
rized inBox2.Amongadherent individuals, initialARTwith2nucleo-
side reverse transcriptase inhibitors (NRTIs) plus a third activedrug
from a different class achieves andmaintains similar virologic sup-
pression rates innearly all patients.22-26Cliniciansandpatientshave
many options and may select a regimen based on considerations
other thanantiviral potency.Considerations includeshort- and long-
termadverse effects, easeof administration, drug interactions, risk
of resistance if virologic failureoccurs, and cost. Patientswithmore
than 100000HIVRNA copies/mL or fewer than 200CD4 cells/μL
remain a subset in whomART potency is particularly important, as
certain regimens have suboptimal virologic suppression in this
setting.1,7,27-35
Optimal Initial Regimens
InSTI-based regimens are optimal for initial therapy. Recom-
mended initial ART for most patients are (regimens are listed in
alphabetic order by InSTI component; see Table 3) dolutegravir/
abacavir/lamivudine (evidence rating AIa), dolutegravir plus
tenofovir alafenamide (TAF)/emtricitabine (AIa), elvitegravir/
cobicistat/TAF/emtricitabine (evidence rating AIa), and raltegravir
plus TAF/emtricitabine (evidence rating AIII). (Components
separated with a slash [/] indicate that they are available as
coformulations.)
If TAF is not available, tenofovir disoproxil fumarate (TDF) is an
effectiveandgenerallywell-toleratedoption.Given the limited long-
termexperiencewithTAF,somecliniciansmayprefertocontinueusing
TDF pending broader experiencewith TAF in clinical practice.
InSTIs as Components of the Initial Regimen
In the SINGLE study, dolutegravir plus abacavir/lamivudinewas su-
perior to efavirenz/TDF/emtricitabine.36 Similar results were ob-
served in the FLAMINGO study (comparing dolutegravir with
ritonavir-boosted [/r] darunavir),37 in the WAVES study (compar-
ing cobicistat-boosted [/c] elvitegravir with atazanavir/r in HIV-
infectedwomen),38 and in theAIDSClinical TrialsGroup5257 study
(comparing raltegravir with atazanavir/r or darunavir/r).39
No clinical trial has directly compared all 3 currently available
InSTIs. In treatment-naive patients, dolutegravir was noninferior
to raltegravir, with no resistance to dolutegravir observed in that
treatment group.40 In treatment-experienced patients, dolute-
gravir was superior to raltegravir41 and elvitegravir was noninfe-
rior to raltegravir.42 The InSTIs differ in several important features
that may influence treatment choice (Table 4).
Abacavir as a Component of the Initial Regimen
Abacavir is a component of the recommended regimen of dolute-
gravir/abacavir/lamivudine. Approximately half of individuals who
are positive for the HLA-B*5701 allele experience a hypersensitiv-
ity reaction to abacavir thatmay be life threatening.44HLA-B*5701
testing should be performed prior to abacavir use (evidence rating
AIa); those who test positive should not be given abacavir (evi-
dence rating AIa). Allergy to abacavir should be listed in the medi-
cal record.
Although some prior comparisons of abacavir/lamivudine and
TDF/emtricitabine demonstrated an efficacy advantage of
TDF/emtricitabine,45,46 these differences have not been observed
in studies that use dolutegravir. In the SINGLE study, all patients in
the dolutegravir-containing group used abacavir/lamivudine.36 In
the SPRING-2 and FLAMINGO studies, a minority of dolutegravir-
treated patients used abacavir/lamivudine, and no differences in
efficacy were found based on NRTI selection.
The association between abacavir and an increased risk of
myocardial infarction remains controversial.1,7,34,35 More studies
have now been published describing the association,47-49 but the
data remain inconclusive. For now, abacavir should be used with
caution in patients who have or who are at high risk of cardiovas-
cular disease.
TAF as a Component of the Initial Regimen
ComparedwithTDF,TAFyieldsa lowerplasma levelof tenofovir and
higher intracellular concentration of the active antiviral compo-
nent tenofovir diphosphate. This results in fewer tenofovir-
Box 1. Recommendations forWhen to Start
Antiretroviral Therapya
• Antiretroviral therapy (ART) is recommended for all viremic
patients with established HIV infection, regardless of CD4
cell count (evidence rating AIa).
• Initiation of ART is recommended as soon as possible
in the setting of acute HIV infection
(evidence rating BIII).
• Planned discontinuation of early ART after a specific duration
of treatment is not recommended outside a research setting
(evidence rating AIa).b
• Initiation of ART is recommended for individuals who have
persistent undetectable viral load without ART but
have declining CD4 cell counts (evidence
rating BIII).
a See text for essential details and cautions.
b The recommendation or the evidence rating has not changed substantially
since the 2014 report.
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associated toxic effects, such as proximal renal tubular toxicity and
reductions in bonemineral density. One report suggested the pos-
sibility of elevated liver enzymes with TDF use, but the clinical sig-
nificance is uncertain.50
TAFandTDFwere compared inprospective clinical trials of ini-
tial therapy51,52 and in switch strategies from TDF in patients with
virologic suppression and no history of resistance or treatment
failure.53,54 To date, only elvitegravir/c has been used in studies of
TAF as initial therapy, but a broader range of third drugs has been
used in switch studies.
Compared with TDF, TAF has little or no effect on bone den-
sity and little or no kidney toxicity. Specifically, proximal tubulopa-
thy has not been observed to date with TAF, which has less effect
on renal tubular and overall proteinuria and estimated glomerular
filtration rate (eGFR) than TDF. TAF reduces lipids less than TDF;
however, this difference does not affect the ratio of total to high-
density lipoprotein cholesterol. To date, no cases of clinical renal
disease are directly ascribed to TAF. Tolerability of TAF and TDF is
comparable, as are rates of HIV suppression, resistance with viro-
logic failure, and increases in CD4 cell count.
The daily dose of TAF (25 mg or 10 mg) is lower than that of
TDF (300 mg). For HIV treatment, TAF is currently available only
in coformulations, consisting of emtricitabine/TAF; rilpivirine/
emtricitabine/TAF; and elvitegravir/cobicistat/emtricitabine/TAF.
Unlike TDF, TAF should not be used with rifamycins, and there are
limited data on its safety and efficacy for pregnant women.
Non–InSTI-Containing (or Non–NRTI-Containing)
Initial Regimens
Several non–InSTI-containing regimens suppress HIV RNA in the
majority of patients who are adherent to therapy. These may be
optimal for a given patient based on individual clinical characteris-
tics, preferences, or owing to financial considerations or lack of
InSTI availability. These regimens are acceptable therapeutic
options. These options are listed in Table 5.
Initial therapy with 2 active drugs is under investigation. This
strategy may offer cost or toxicity advantages over the current
3-drug regimens.56 To date, only 2 adequately powered random-
ized clinical trials have demonstrated noninferior outcomes of
2-drug therapy compared with 3-drug regimens. Lopinavir/r plus
lamivudine was noninferior to lopinavir/r plus 2 NRTIs in one
study,57 and darunavir/r plus raltegravir was noninferior to
darunavir/r plus 2 NRTIs in another.58 However, these 2-drug regi-
mens have limitations. Lopinavir/r induces relatively high rates of
gastrointestinal adverse effects and hyperlipidemia. Darunavir/r
plus raltegravir was associated with higher rates of treatment fail-
ure in patients with a CD4 cell count below 200/μL or an HIV RNA
level above 100 000 copies/mL. A small single-group trial of
dolutegravir plus lamivudine in 20 patients demonstrated prom-
ising results.59
Initial 2-drug regimens are recommended only in the rare
situations in which a patient cannot take abacavir, TAF, or TDF
(evidence rating BIa); [darunavir/c or darunavir/r] plus [raltegravir
Table 2. Summary Results of 3 Key Randomized Clinical Trials of Immediate vs Deferred Antiretroviral Therapy (ART)
in ART-Naive HIV-Infected Individuals
Source
No. of Participants
in Study (CD4 Cell
Count Parameter)
Duration of
Follow-up, mo Study End Point
No. (%) With Outcome
in Immediate ART Group
No. (%) With Outcome
in Deferred ART Group
Hazard Ratio (95% CI)
for Immediate vs
Deferred ART
Lundgren
et al,2 2015
4685 (>500/μL) 36 Primary end point
(AIDS,
serious
non–AIDS-related
events, death)
42 (1.8)
[0.6/100 patient-years
of observation]
96 (4.1)
[1.38/100 patient-years
of observation]
0.43 (0.3-0.62)
AIDS-related events 14 (0.6) 50 (2.1) 0.28 (0.15-0.50)
Serious
non–AIDS-related
events
29 (1.3) 47 (2.0) 0.61 (0.38-0.97)
All-cause mortality 12 (0.5) 21 (0.9) 0.58 (0.28-1.17)
Danel et al,3
2015
2056 30 Primary end point
(AIDS,
non–AIDS-related
cancer or bacterial
disease, death)
64 (6.2)
[2.8/100 patient-years
of observation]
111 (10.9)
[4.9/100 patient-years
of observation]
0.56 (0.41-0.76)
AIDS-related events 33 (3.2) 65 (6.4)
Mortality 21 (2.0) 26 (2.5)
843
(Baseline >500/μL)
30 Subgroup of participants
with baseline CD4 cell
count >500/μL (primary
end point)
23 (2.2)
[2.4/100 patient-years
of observation]
38 (3.7)
[4.1/100 patient-years
of observation]
0.56 (0.33-0.94)
Grinsztejn
et al,8 2014
1763
(350/μL-550/μL)
24 Primary end point
(AIDS,
non–AIDS-related
events, severe bacterial
infections, death)
57 (6.4) 77 (8.8) 0.73 (0.52-1.03)
AIDS 40 (4.5) 61 (7.0) 0.64 (0.43-0.96)
Non–AIDS-related
events
12 (1.4) 9 (1.0) 1.35 (0.57-3.19)
Death 11 (1.2) 15 (1.7) 0.73 (0.34-1.59)
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or dolutegravir] or plus [lamivudine or emtricitabine] may be con-
sidered, but the former strategy may be less effective in those
with CD4 cell counts below 200/μL or HIV RNA levels above
100000 copies/mL. Of note, there are no adequately powered
studies of initial therapy of other listed 2-drug regimens besides
darunavir/r plus raltegravir or lopinavir/r plus lamivudine; efficacy
is assumed from other clinical trials.57,58
Special Considerations
Pregnancy
HIV-infected pregnant women should initiate ART for their own
health and to reduce the likelihood of HIV transmission to the
infant (evidence rating AIa). Nucleoside reverse transcriptase
inhibitor options include abacavir/lamivudine (if the patient is
HLA-B*5701 negative), TDF/emtricitabine, or zidovudine/
lamivudine. Zidovudine/lamivudine is the regimen with the lon-
gest clinical experience, but it has more toxic effects. Raltegravir is
the recommended InSTI for use during pregnancy. Recommended
boosted PIs include atazanavir/r (once daily) or darunavir/r (twice
daily). The recommended NNRTI is efavirenz when initiated after
the first 8 weeks of pregnancy. If an HIV-infected woman who is
taking efavirenz becomes pregnant, the regimen may be contin-
ued; changing it risks loss of virologic control.
Hepatitis B Virus Coinfection
HIV-infectedpatientswithhepatitisBvirus (HBV)coinfectionshould
initiate a recommended ART regimen that contains TDF or TAF
(evidence rating AIa), lamivudine or emtricitabine, and a third
component.60-62Lamivudineandemtricitabineeachhavesubstan-
tial antiviral activityagainstHBV.However, there is ahigh riskofHBV
resistance and viral breakthrough if these drugs are used without
TDF or TAF, and neither is recommended alone for HBV in coinfec-
tion. Entecavir may be used to treat HBV infection (evidence
ratingAIII). IfHIVRNAisnotsuppressed,entecavir shouldbeavoided
because it canselect for lamivudine-andemtricitabine-resistantHIV
(evidence rating AIII).
Hepatitis C Virus Coinfection
HIV-infectedpatientswithhepatitisCvirus (HCV)coinfectionshould
start an ART regimen with drugs that do not have significant drug
interactionswith HCV therapies (evidence rating AIIa). The recom-
mended regimens that have the fewest drug interactionswith cur-
rent HCV treatments are dolutegravir/abacavir/lamivudine and
dolutegravir or raltegravir plus TAF/emtricitabine. Clinicians should
consult current HCV treatment guidelines prior to using any other
ART regimens, particularly those that includeNNRTIs, boostedHIV
PIs, or elvitegravir/c.63
Box 2. Recommendations for Initial ART Regimensa
• Recommended initial regimens (listed in alphabetic order by InSTI
component):
• Dolutegravir/abacavir/lamivudine (evidence rating AIa)
• Dolutegravir plus TAF/emtricitabine (evidence rating AIa)b
• Elvitegravir/cobicistat/TAF/emtricitabine (evidence rating AIa)b
• Raltegravir plus TAF/emtricitabine (evidence rating AIII)
• HLA-B*5701 testing should be performed prior to abacavir use
(evidence rating AIa); those who test positive should not be given
abacavir (evidence rating AIa).
• Tenofovir disoproxil fumarate is not recommended for individuals
with or at risk of kidney or bone disease (osteopenia or osteoporosis)
(evidence rating BIII).
• Recommended initial regimens for individuals in whom an InSTI
is not an option (listed in alphabetic order by InSTI component):
• Darunavir (boosted) plus TAF (or TDF)/emtricitabine or abacavir/
lamivudine (evidence rating AIa)b
• Efavirenz/TDF/emtricitabine (evidence rating AIa)
• Rilpivirine/TAF (or TDF)/emtricitabine (evidence rating AIa)b
• Initial 2-drug regimens are recommended only in rare situations
in which a patient cannot take abacavir, TAF, or TDF
(evidence rating BIa).
• HIV-infected pregnant women should initiate ART for their own
health and to reduce the likelihood of HIV transmission to their
infant (evidence rating AIa).c
• For HIV-infected patients with hepatitis B virus coinfection should
initiate ART that contains TDF or TAF (evidence rating AIa),
lamivudine or emtricitabine, and a third component
(evidence rating AIa).
• Entecavir may be used to treat hepatitis B virus infection
(evidence rating AIII). If HIV RNA is not suppressed, entecavir
should be avoided because it can select for drug-resistant HIV
(evidence rating AIII).
• HIV-infected patients with hepatitis C virus coinfection should start
an ART regimen with drugs that do not have significant drug
interactions with hepatitis C virus therapies (evidence rating AIIa).
• Tenofovir disoproxil fumarate is not recommended for patients
with osteopenia or osteoporosis (evidence rating BIII).
• Monitoring for development of kidney disease with estimated
glomerular filtration rate, urinalysis, and testing for glycosuria and
albuminuria or proteinuria is recommended when ART is initiated
or changed and every 6months (along with HIV RNA) once HIV
RNA is stable (evidence rating BIII).
• Tenofovir disoproxil fumarate should be avoided or dose adjusted
in patients with a creatinine clearance rate below 60mL/min
(evidence rating AIa).
• Tenofovir alafenamide is not recommended in patients with
a creatinine clearance rate below 30mL/min (evidence rating AIa).
• Tenofovir disoproxil fumarate or TAF should be discontinued if
a patient’s renal function worsens, particularly if there is evidence
of proximal tubular dysfunction (evidence rating AIIa).
• HIV-infected patients with end-stage renal disease should be
evaluated for kidney transplantation with expectation of high rates
of patient and graft survival (evidence rating AIIa).
Abbreviations: ART, antiretroviral therapy; InSTI, integrase strand transfer;
TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
a See text for essential details and cautions. Components separated with
a slash (/) indicate that they are available as coformulations.
b TDFmay be substituted for TAF if TAF is not available for the patient.
c The recommendation or the evidence rating has not changed substantially
since the 2014 report.
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Bone Disease
Osteoporosis and fractures are increasedwithHIV infection.64Dur-
ing the first 1 to 2 years after initiation of ART, patientsmay lose 2%
to 6% of their bone mineral density at the hip and spine. Patients
who receive TDF-containing regimens have a greater initial decline
in bone mineral density than those who take a TAF- or abacavir-
containing regimen. For this reason, TDF is not recommended for
patients with osteopenia or osteoporosis (evidence rating BIII).
Kidney Disease
Monitoring for development of kidney disease with eGFR, urinaly-
sis, and testing for glycosuria and albuminuria or proteinuria is
recommended when ART is initiated or changed and every 6
months (along with HIV RNA) once HIV RNA is stable (evidence
rating BIII).65 In cohort studies, TDF (especially with a boosted PI)
increased the risk of chronic kidney disease.66 Tenofovir diso-
proxil fumarate is not recommended for patients with an eGFR
below 60 mL/min.65 The options are abacavir (which does not
require dose adjustment in this setting) or TAF (if creatinine clear-
ance is above 30 mL/min) (evidence rating AIIa). Long-term data
on TAF in patients with preexisting renal disease are limited.67
Tenofovir disoproxil fumarate or TAF should be discontinued if
renal function worsens, particularly if there is evidence of proxi-
mal tubular dysfunction (eg, euglycemic glycosuria or urinary
Table 3. Recommended Initial Antiretroviral Therapy Regimensa
Regimen Rating
Dolutegravir/abacavir/lamivudine AIa
Dolutegravir plus tenofovir alafenamide/emtricitabineb AIa
Elvitegravir/cobicistat/tenofovir alafenamide/emtricitabineb AIa
Raltegravir plus tenofovir alafenamide/emtricitabineb AIII
a Regimens are listed in alphabetic order by integrase strand transfer inhibitor
component. Components separated with a slash (/) indicate that they are
available as coformulations.
b In settings in which tenofovir alafenamide/emtricitabine is not available,
tenofovir disoproxil fumarate (with emtricitabine or lamivudine) remains an
effective and generally well-tolerated option. Given the limited long-term
experience with tenofovir alafenamide, some clinicians may prefer to continue
using tenofovir disoproxil fumarate pending broader experience with
tenofovir alafenamide in clinical practice.
Table 4. Advantages and Disadvantages of Currently Available Integrase Strand Transfer Inhibitors
Dolutegravir Elvitegravir Raltegravir
Year of US Food and
Drug Administration
approval
2013 2012 2007
Advantages Superior to efavirenz and ritonavir-boosted
darunavir in comparative clinical trials36,37
Once-daily dosing
Coformulated with abacavir/lamivudine as part
of a complete initial regimen
Dolutegravir (not coformulated) pill size is small
Lowest risk of resistance with virologic failure36,37,40,43
Relatively few drug interactions
Can be taken with or without food
Superior to raltegravir in treatment-experienced patients
Superior to ritonavir-boosted atazanavir
in comparative clinical trial
in HIV-infected women38
Once-daily dosing
Coformulated with tenofovir disoproxil
fumarate/emtricitabine or tenofovir
alafenamide/emtricitabine as
a complete regimen
Superior to ritonavir-boosted
atazanavir and
ritonavir-boosted darunavir
in comparative clinical trial39
Longest safety record
Fewest drug interactions
Can be taken with or
without food
Disadvantages Only available coformulation is with abacavir/lamivudine
Raises serum creatinine owing to inhibition
of tubular secretion of creatinine
Higher rates of insomnia and headache than comparators
in some studies36,37
Largest tablet among coformulated
single-pill regimens
Requires pharmacokinetic boosting with
cobicistat or ritonavir for once-daily
dosing
Most drug interactions
Cobicistat raises serum creatinine owing
to inhibition of tubular secretion
of creatinine
Should be taken with food
Currently must be taken twice
daily (formulation consisting
of 2 pills given once daily
in development)
Not coformulated as part
of a complete regimen
Table 5. Advantages and Disadvantages of Initial Antiretroviral Therapy Options for Patients inWhom InSTIs Are Not an Optiona
Darunavir (Boosted With Cobicistat
or Ritonavir) Plus TAF/Emtricitabine,
TDF/Emtricitabine,
or Abacavir/Lamivudineb Efavirenz/TDF/Emtricitabine Rilpivirine/TAF (or TDF)/Emtricitabine
Advantages Low risk of resistance with virologic failure,
even with intermittent adherence
High efficacy in patients with baseline HIV
RNA >100 000 copies/mL
Extensive experience in patients with
concomitant tuberculosis
Widely available globally
Lowest risk of rash among NNRTI-based
therapies
Low risk of metabolic adverse effects
Smallest tablet among single-pill regimens
Disadvantages Requires pharmacokinetic boosting;
many drug interactions
Ritonavir-boosted darunavir inferior to
raltegravir and dolutegravir in separate
comparative clinical trials37,39
Results of comparative, fully powered
studies of cobicistat-boosted darunavir
as initial therapy are not yet available
Relatively high rate of rash
No single-tablet form available with TAF
High rates of neuropsychiatric adverse effects
Increased risk of suicidality in 1 study55;
avoid in patients with history of depression
Not recommended for patients with HIV RNA
>100 000 copies/mL or CD4 cell count
<200/μL owing to increased risk of virologic
failure
Must be taken with a meal to optimize
absorption
Should not be administered with proton pump
inhibitors; stagger dosing if given with
an H2 blocker
Abbreviations: InSTI, integrase strand transfer inhibitor; NNRTI, nonnucleoside
reverse transcriptase inhibitor; TAF, tenofovir alafenamide; TDF, tenofovir
disoproxil fumarate.
a Nonnucleoside reverse transcriptase inhibitor–based regimens should not be
used without baseline resistance data because of the possible presence of
transmitted NNRTI-resistant virus. In the rare circumstance in whichmaraviroc
might be included in initial therapy, initiation should not occur before
confirmation of CC chemokine receptor 5 tropism.
bCautions on the use of abacavir and TAF or TDF are described in the text.
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phosphate wasting) (evidence rating AIIa). The safety of TAF in
patients with active TDF-associated proximal tubulopathy has not
been determined. If possible, TAF should be initiated only after
tubulopathy has resolved, with monitoring for recurrence. HIV-
infected patients with end-stage renal disease should be evalu-
ated for kidney transplantation with the expectation of high rates
of patient and graft survival (evidence rating AIIa).
Cost Considerations
In highly resourced countries, approximately 75% to 80% of an-
nualHIV care expenditures are spentonmedications.68Evenat full
price, ART is cost-effective.69 In theUnited States, drugpricingdis-
counts are common, but the amountof discount remains unknown
to clinicians andpatients,making it difficult to usepricing as a com-
ponent of treatment decisions.
Asmore drugs become available in less-expensive generic for-
mulations, payers may begin to use “societal benefit” as a criterion
for selection of the initial regimen. One modeling study showed a
savings of up to $900million annuallywith routine useof a generic
efavirenz-based regimen in the United States over a branded ver-
sion of the same regimen.70 Although relative efficacy in viral sup-
pression is lowerwith an efavirenz-based regimen thanwith InSTI-
basedregimens, thedifferencesaremodestanddrivenbytolerability
rather than potency.71
Where resource constraints limit the ability of a health system
toprovidewidespread treatment toallHIV-infectedpersons, a strat-
egy of using generic formulations of recommended regimens first
with use of more expensive drugs for those who demonstrate in-
tolerance may be reasonable. Such policy decisions should be de-
termined in consultation with HIV experts in the locale where the
policy is being considered.
Interface of ART and OIs
When to Start ART in the Setting of Active OIs
Recommendations for ART in the setting of OIs are summarized in
Box 3. ART should be started as soon as possible but within the first
2 weeks after diagnosis for most OIs,1 with the possible exception
of acute cryptococcal meningitis (evidence rating AIa). In a ran-
domized clinical trial of ART initiation in the setting of cryptococcal
meningitis in resource-constrained settings, mortality was higher
when ART was started within the first 1 to 2 weeks of diagnosis;
mortality was lower when ART was delayed until 5 weeks after
diagnosis.72 However, in the United States, Canada, and Europe,
where there may be greater access to optimal antifungal therapy
(eg, flucytosine),73 frequent monitoring, and appropriate manage-
ment of high intracranial pressure and other underlying conditions,
earlier initiation of ART, within 2 weeks of diagnosis, is preferred.74
Although a randomized clinical trial found no survival benefit of
early initiation of ART for HIV-infected persons with active tubercu-
losis and CD4 cell counts greater than 220/μL,75 there was no
increased harm, and the improved survival observed in the SAPiT,
CAMELIA, and STRIDE trials, particularly for those with lower CD4
cell counts,1,76-78 supports the recommendation to start ARTwithin
the first 2 weeks of initiation of tuberculosis treatment for those
with CD4 cell counts of 50/μL or less and within the first 2 to
8 weeks for those with CD4 cell counts above 50/μL (evidence rat-
ing AIa). Of note, earlier initiation of ART in persons with active
tuberculosis, particularly tuberculosis meningitis, may be associ-
ated with higher rates of immune reconstitution inflammatory syn-
drome and may complicate management of adverse drug
reactions,79 thus mandating careful monitoring in this setting.
Recommended Initial ART in the Setting of OIs
Drug interactionsandtolerabilityare importantconsiderationswhen
choosing an initial ART regimen in persons with an acute OI. Azole
antifungal agents and rifamycins are of particular concern. The
choices for ART in the setting of rifamycin-based antituberculosis
therapy have been expanded; efavirenz, 600mg daily; raltegravir,
400mg twice daily; or dolutegravir, 50mg twice daily in combina-
tion with 2 NRTIs are acceptable, with InSTI-based regimens
recommended.76-78,80-83 Neither TAF nor elvitegravir/c is recom-
mendedwith rifamycindrugsbecauseof potential adversedrug in-
teractions (evidenceratingAIIb).AboostedPI–basedregimenshould
be used only if an InSTI-based regimen is not an option, and rifabu-
tin, 150 mg daily, should be substituted for rifampin in the antitu-
berculosis regimen (evidence rating AIa).84-86
A 3-month, once-weekly regimen of isoniazid and rifapentine
for treatment of latent tuberculosis infection is as effective as 9
months of isoniazid alone in HIV-infected individuals.87-89 High-
dosedaily rifapentine canbe safely administeredwith efavirenz, al-
lowing the 3-month regimen to be administered with efavirenz-
basedART.80,90Although raltegravir exposurewas increasedwhen
administeredwithonce-weekly rifapentine,91 the regimenwaswell
tolerated, supporting use of raltegravir-based regimens. There are
no pharmacokinetic data on rifapentine with dolutegravir. How-
ever, extrapolation fromavailable data on rifampin and the similari-
ties between rifapentine and rifampin pharmacokinetics supports
dolutegraviruse in thiscontext,withsimilardoseadjustmentsassug-
gested for antituberculosis therapy.
Box 3. ART andOpportunistic Infection Recommendationsa
• ART should be started within the first 2 weeks after diagnosis for
most acute opportunistic infections, with the possible exception
of acute cryptococcal meningitis (evidence rating AIa).b
• ART should be started within the first 2 weeks of initiation
of tuberculosis treatment for those with CD4 cell counts of 50/μL
or less and within the first 2 to 8 weeks for those with CD4 cell
counts above 50/μL (evidence rating AIa).
• Neither tenofovir alafenamide nor cobicistat-boosted elvitegravir
is recommended with rifamycin drugs (evidence rating AIIb).
A boosted protease inhibitor–based regimen should be used
only if an integrase strand transfer inhibitor is not an option,
and rifabutin, 150mg/d, should be substituted for rifampin
in the antituberculosis regimen (evidence rating AIa).
• PrimaryMycobacterium avium complex prophylaxis is not
recommended if effective ART is initiated immediately and viral
suppression achieved (evidence rating AIIa).
• Primary Pneumocystis pneumonia prophylaxis is recommended
for patients whomeet CD4 cell count criteria (evidence
rating AIa), even if taking ART.
Abbreviation: ART, antiretroviral therapy.
a See text for essential details and cautions.
b The recommendation or the evidence rating has not changed substantially
since the 2014 report.
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CD4 Cell CountMonitoring and Primary OI Prophylaxis
Recommendations regardingwhen to initiate, whether to continue,
and when to stop prophylaxis for OIs have been based on CD4 cell
counts prior to and after initiation of ART. With ART recommended
for all HIV-infected persons regardless of CD4 cell count, the inci-
dence of AIDS-associated OIs and associated mortality continues
todecline. Forpersonsachievingvirologic suppressionwithART, the
incidence ofMycobacterium avium complex (MAC) disease has de-
clinedsufficientlythatmortality isnotsubstantiallydifferentonceMAC
disease develops for those who did vs did not receive primary MAC
prophylaxis.92,93 Thus, primary MAC prophylaxis is not recom-
mendedifeffectiveARTis initiatedimmediately(evidenceratingAIIa).
Although similar trends are seen with Pneumocystis jirovecii pneu-
monia aswithMAC,92,94 Pneumocystispneumonia is themost com-
mon AIDS-related OI and carries a higher risk of earlymortality than
MACdisease.92 Intheabsenceofstrongerdata, initiatingprimarypro-
phylaxis forPneumocystispneumonia is still recommendedfor those
whomeet CD4 cell count criteria (evidence rating AIa).
When and How to Switch
Recommendations for when and how to switch antiretroviral regi-
mensaresummarized inBox4.With improvements inART, theneed
toswitch therapybecauseofvirologic failureanddrug resistancehas
decreased. However, these improvements provide a rationale for
switching therapy in some patients who have virologic suppres-
sionwitholder regimens that are less convenient or that havemore
adverse or toxic effects. Reasons to consider switching therapy in
suchpatients includeadverseeffects, simplification (reducingdoses
or pills), drug-drug interactions, pregnancy or plans for pregnancy,
and food restrictions.
Study data support switching froman older regimen to one of a
number of single-pill regimens: dolutegravir/abacavir/lamivudine,95
elvitegravir/cobicistat/emtricitabine/TAF,53 elvitegravir/cobicistat/
emtricitabine/TDF,96,97 or rilpivirine/emtricitabine/TDF.98 Data also
support a switch from suppressive TDF/emtricitabine–based regi-
mens to TAF/emtricitabine–based regimens.60 The lack of random-
izedclinical trialdatadoesnotprecludethepossibilityofaswitch,pro-
vided certain caveats are considered.
Induction maintenance approaches have been evaluated in
whichpatientswith virologic suppression switch froma3-drug to a
2-drugmaintenanceregimen.99-102Althoughtrialsprovidesomesup-
port for thisapproach, it remains investigational, and inductionmain-
tenance strategies are not recommended at this time (evidence
rating BIIa).
For patients experiencing adverse effects or drug toxicities or
requesting modification or simplification of their regimen, the de-
cision to switch is relatively easy. Situations exist in which practi-
tioners should recommend a switch even for patients who are sat-
isfiedwith their current regimenandappear tobedoingwell. These
includewhenpatients are taking regimenscontaining stavudine,di-
danosine, or zidovudine, largely because of long-term toxic ef-
fects, or older PIs that have higher pill burdens and greater meta-
bolic toxicities thandarunavir or atazanavir. Somedrugs that areno
longer recommended for initial use may often be safely continued
forpatientswhoare tolerating them.For example, althoughnevira-
pine andefavirenzhave substantial early toxic effects, they are safe
and tolerable in the long term. Patients taking efavirenz should be
questioned carefully about the possibility of subtle neuropsychiat-
ric adverse effects (eg, dizziness, sleep disturbances, cognitive
changes, depression) that they may be unaware of or may not at-
tribute to the drug (evidence rating BIII).
With the availability of TAF in its coformulations, it is possible
to switch fromTDF toTAF.Although thepresumptionof greater re-
nal andbonesafety isprimarilybasedonsurrogatemarkers (ie,bone
density as amarker for fracture risk; eGFR and proteinuria for renal
safety), these markers consistently suggest superior safety of TAF
vs TDF. One exception may be modest lipid elevations due to the
loss of the lipid-lowering effects of TDF. If there is no increase in the
price of TAF vs that of TDF, switching from TDF to TAF is reason-
able even if patients are not experiencing TDF-related toxic effects
(evidence rating BIa).
For patients with virologic suppression, it is important to con-
sider thepossibility of drug resistanceandwhether thegenetic bar-
riers to resistanceof theexisting andproposed switch regimens are
high or low. The risk of switching from a high-barrier regimen to a
low-barrier regimen inpatientswithpreexistingdrug resistancehas
been well demonstrated.103 When possible, switches to a regimen
with a lower resistancebarrier shouldbemadeonly after reviewing
thetreatmentandresistancehistory (evidenceratingAIa).Whenthis
information is not available, a proviral DNA genotype test may be
helpful. The clinical utility of these assays has not yet been estab-
lished,but theymaybeuseful indetectingmutations thathavebeen
archived in resting CD4 cells but that are no longer detectable by
standard commercial resistance assays.104,105 Results must be in-
Box 4. Recommendations forWhen andHow to Switch
Antiretroviral Regimensa
• Data support possible switching from an older regimen to a
single-pill regimen in certain patients with virologic suppression
(see text).b
• Inductionmaintenance strategies (switching from 3- to 2-drug
regimens in patients with virologic suppression [see text]) are
not recommended at this time (evidence rating BIIa).
• Patients taking efavirenz should be questioned carefully about
the possibility of subtle neuropsychiatric adverse effects
(eg, dizziness, sleep disturbances, cognitive changes,
depression) that theymay be unaware of or may not attribute to
the drug (evidence rating BIII).
• Review of treatment history and results of prior resistance tests
is recommended before any treatment switches are made
(evidence rating AIa).
• If there is no increase in price, switching from tenofovir disoproxil
fumarate (TDF) to tenofovir alafenamide is reasonable even if
patients are not experiencing TDF-related toxic effects (evidence
rating BIa).
• Switching from a boosted protease inhibitor to a nonnucleoside
reverse transcriptase inhibitor or an integrase strand transfer
inhibitor (with the possible exception of dolutegravir) or
switching from twice-daily ritonavir-boosted darunavir to
once-daily cobicistat-boosted darunavir is not recommended
without consideration of a patient’s viral resistance profile
(evidence rating AIII).
a See text for essential details and cautions.
b The recommendation or the evidence rating has not changed substantially
since the 2014 report.
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terpreted with caution because they can sometimes fail to detect
existingmutations.106Someswitches in the settingof viral suppres-
sionmaybe safe regardless of resistance (eg, TDF to TAF, efavirenz
to rilpivirine or etravirine, raltegravir or elvitegravir to dolutegravir,
or lopinavir/r toboosteddarunavir). Switching fromaboostedPI to
an NNRTI or an InSTI (with the possible exception of dolutegravir)
or switching from twice-daily darunavir/r to once-daily darunavir/c
is not advisedwithout considering resistancehistorybecauseof the
reduced resistance barrier of the regimen (evidence rating AIII).
The drug-drug interactions that affect the choice of initial regi-
menalsomustbe consideredwhenswitching.Whetherbaselinevi-
ral load should be considered before switching therapy is not clear;
baseline HIV RNA levels above 100000 copies/mLwere not asso-
ciated with virologic failure when patients with virologic suppres-
sion with a PI-based regimen switched to a rilpivirine-containing
regimen.98
The approach to virologic failure of an initial NNRTI-, PI-, or
InSTI-based regimen has been addressed previously.1 Failure of ini-
tial regimens thatwere chosenbasedonbaseline resistance test re-
sults is generally due topoor adherenceor, less commonly, todrug-
drug interactions. Thus, adherence and drug interactions must be
addressed before initiating the new regimen.
Laboratory Monitoring
Initiation of Therapy
Recommendations for laboratory monitoring are summarized in
Box 5. As close to the time of HIV diagnosis as possible and prior to
beginningART,CD4cell count,plasmaHIVRNA, serologies forhepa-
titis A, B, andC, serumchemistries, estimated creatinine clearance,
completebloodcell count, andurineglucose andprotein shouldbe
measured (evidence ratingAIII). Genotypic resistanceassays for re-
verse transcriptase and protease should be ordered for all patients
(evidence rating AIIa). Transmitted resistance to InSTIs has been
documented but is uncommon at present, with little increase over
time107-109; thus, routine pretreatment screening for integrase re-
sistance is not currently recommendedunless there is reason tobe-
lieve that the infecting virusmayhave come fromasource inwhom
InSTI-containing treatment failed (evidence rating BIII).1 Screening
for syphilis and 3-site (as appropriate) mucosal nucleic acid ampli-
fication testing for chlamydiaandgonorrheashouldalsooccurat the
time of HIV diagnosis, and a fasting lipid profile should be obtained
(evidence rating AIII). Other laboratory assessments should be in-
dividualized, inkeepingwithcurrentguidelines.110,111HLA-B*5701and
CC chemokine receptor 5 tropism testing results must be con-
firmed prior to initiating therapy with abacavir and maraviroc,
respectively.1
IfART isbeing initiatedonthefirstclinicvisit, all laboratoryspeci-
mens shouldbedrawnprior to the first doseofART; resistance test-
ing results should be used to modify the regimen as necessary
(evidence ratingAIII). A similarprocess shouldbeused for rapidART
initiation for acute or advanced HIV infection.
Ongoing Therapy
HIV RNA level should bemonitored every 4 to 6weeks after treat-
ment is initiated or changed until it is undetectable, generally be-
low 20 to 50 copies/mL (evidence rating AIa). Virologic suppres-
sion should occur within 24 weeks of ART initiation even when
initiatedduringacute infection.112 Failure to achieve suppressionby
24weeks should prompt evaluation for virologic failure. After sup-
pression is achieved,HIVRNAshouldbemonitoredevery3months
Box 5. Recommendations for LaboratoryMonitoringa
• Recommended pre-ART tests include CD4 cell count, plasma
HIV-1 RNA, serologies for hepatitis A, B, and C, serum
chemistries, estimated creatinine clearance rate, complete blood
cell count, urine glucose and protein, sexually transmitted
infection screening, and fasting lipid profile (evidence rating AIII).
• Genotypic testing for reverse transcriptase and protease
resistancemutations is recommended prior to treatment
initiation (evidence rating AIIa).
• Routine screening for integrase resistance is currently not
recommended prior to treatment initiation unless the source
virus is suspected to have been from someone in whom
treatment containing an integrase strand transfer inhibitor failed
(evidence rating BIII).
• Screening for syphilis and 3-site (as appropriate) mucosal nucleic
acid amplification testing for chlamydia and gonorrhea should
occur at the time of HIV diagnosis and a fasting lipid profile
should be obtained (evidence rating AIII).
• If ART is initiated on the first clinic visit, all laboratory specimens
should be drawn prior to the first dose of ART; resistance testing
results should be used tomodify the regimen as necessary
(evidence rating AIII).
• HIV RNA level should bemonitored every 4 to 6 weeks after
treatment is initiated or changed until virus is undetectable
(evidence rating AIa).b
• Therapeutic drugmonitoring is not recommended except in
specific circumstances (evidence rating BIII).b
• After viral suppression is achieved, HIV RNA should be
monitored every 3months until suppressed for 1 year and at least
every 6months thereafter for adherent patients who remain
clinically stable (evidence rating AIII).
• If pretreatmentCD4cell count is below200/μL, reassessment is
recommendedevery 3 to4monthsuntil viral load is reliably
suppressedandCD4cell count is above350/μL for 1 year.
Thereafter, CD4cell counts shouldbeassessedat6-month intervals
until virus hasbeen suppressed for at least 2 years andCD4cell
count is persistently stable above500/μL (evidence ratingAIII).
• When virus has been suppressed for at least 2 years andCD4 cell
count is persistently above 500/μL, repeatmonitoring of CD4 cell
count is not recommendedunless virologic failure (evidence rating
AIIa) or intercurrent immunosuppressive conditions occur or
immunosuppressive treatments are initiated (evidence ratingAIII).
• If the HIV RNA level remains above the limit of quantification by
24 weeks after starting new treatment or if rebound above
50 copies/mL occurs at any time, the assay should be repeated
within 4 weeks to exclude impending virologic failure (evidence
rating AIIa).
• Tropism testing is recommended at the time of virologic failure of
a CC chemokine receptor 5 inhibitor (evidence rating AIa).
• For patients with persistent quantifiable HIV RNA between 50
and 200 copies/mL, reassessment for causes of virologic failure,
evaluation again within 4 weeks, and close monitoring are
recommended (evidence rating BIII).b
Abbreviation: ART, antiretroviral therapy.
a See text for essential details and cautions.
b The recommendation or the evidence rating has not changed substantially
since the 2014 report.
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until suppression has been sustained for 1 year and at least every 6
months thereafter foradherentpatientswhoremainclinically stable
(evidence rating AIII). Therapeutic drug monitoring is not recom-
mended except in specific circumstances, as previously described
(evidence rating BIII).1
CD4 cell count is used to determine the need for OI prophy-
laxis. If pretreatment CD4 cell count is below 200/μL, reassess-
ment is recommendedevery 3 to4monthsuntil HIVRNA is reliably
suppressed and CD4 cell count is above 350/μL for 1 year. Thereaf-
ter, CD4 cell counts should be assessed at 6-month intervals until
virus has been suppressed for at least 2 years and CD4 cell count is
persistently stable above 500/μL (evidence rating AIII). Subse-
quently, repeatmonitoring isnot recommendedunlessvirologic fail-
ure or intercurrent immunosuppressive conditions occur or immu-
nosuppressive treatments are initiated (evidence rating AIII).1,113
Monitoring for safety, includingmeasuresof renal andhepatic func-
tion and fasting lipids, should be individualized based on age, co-
morbidconditions, andconcurrentmedications. Screening for sexu-
ally transmitted infections should be conducted according to
guidelines, local prevalence, and patient risk.114
Virologic Failure
Virologic failure isdefinedasaconfirmedplasmaHIVRNAabove200
copies/mL. If the HIV RNA level remains above the limit of quanti-
ficationby24weeksor if reboundabove50copies/mLoccursatany
time, the assay should be repeated within 4 weeks to exclude im-
pending virologic failure (evidence ratingAIIa). The clinician should
discuss adherence and tolerability with the patient and review the
completemedication list, includingnonprescribed supplements, to
ensure thatdrug-drug interactionsarenot compromising therapeu-
tic efficacy. Drug-food interactions should also be explored. Geno-
typic resistance testing should occur at the time of confirmed viro-
logic failure, although amplification may not be successful for HIV
RNA levels below 500 to 1000 copies/mL; proviral DNA assays to
estimate archived resistance may be considered. With CC chemo-
kine receptor 5 inhibitors, tropism testing is recommended at the
timeof virologic failure (evidence ratingAIa). CD4cell count assess-
ment is recommended in the settingof viral rebound (evidence rat-
ing AIIa).
Management of Low-Level Viremia
Although any detectable virus has been associated with viral
rebound in some studies,115,116 measurable HIV RNA between 20
and 50 copies/mL did not increase the risk of virologic failure in 1
study.117 Data are inconsistent about long-term effects of persis-
tent HIV RNA between 50 and 200 copies/mL,116,118 and current
data are insufficient to guide clinical management. Such patients
should be reassessed for causes of virologic failure, evaluated
again within 4 weeks, and monitored closely (evidence rating
BIII). Decisions to change therapy should be individualized based
on ART options, resistance history, and clinical circumstances.
Treatment should be changed in patients with persistent HIV RNA
above 200 copies/mL.119
Viral Resistance
Although transmitted viruseswith resistancemutations can revert
to wild type, baseline resistance testing should be performed re-
gardless of the duration of infection becausemanymutations have
little effect on viral fitness and may persist for years.120-122 Non-
nucleoside reverse transcriptase inhibitor mutations are the most
commontransmittedresistancemutations(4.5%-10%);NRTI (4.0%-
4.5%) and PI mutations are less common (2.8%-3.4%).107,123 Viro-
logic failurewith an InSTI-containing regimen requires integrase re-
sistance testing, as integrase resistancehasbeendescribed inup to
6.8%ofpatients.124Resistance testing is less reliable if apatienthas
stoppedART for longer than 1monthwhen the sample is collected.
The absence of resistance mutations does not confirm absence of
resistance in this setting.
Engagement in Care and ART Adherence
Recommendations for engagement in care andART adherence are
summarized in Box 6.
Achieving the full benefits of treatment and prevention af-
forded by ART requires early diagnosis, rapid linkage to care, con-
tinuous retention in care, and uninterrupted access and adherence
toART. Latediagnosis andpresentation forHIVcare areglobal chal-
lenges that have improved only modestly over decades.125,126 To
avoidmissed opportunities for earlier diagnosis,127 routine opt-out
HIVscreening is recommended inprimarymedical care settingsand
emergencydepartments and for all pregnantwomen (evidence rat-
ing AIII).128,129
Even in highly resourced settings such as the United States,
roughly 90% of new HIV infections are attributable to individuals
with undiagnosed infection (30%) or who have received a diagno-
sis but are not engaged in HIV care (61%).130 Systematic monitor-
ingof time fromdiagnosis to care linkage, retention in care,ARTad-
herence, and rates of viral suppression is recommended to identify
andaddressbarriersandtooptimize individualandpublichealthout-
comes (evidence rating AIIa).7
Monitoring through integration of surveillance data with clini-
caldatasystemsshowspromise in improvinghealthoutcomes.Real-
time surveillance-basedmessaging throughanHIVhealth informa-
tion exchange has increased engagement rates for individualswho
wereno longer inHIVcarebutwere receivingnon-HIVmedical care
at nearby sites.131 Coordinationwithpublic health surveillancedata
systems is important, when possible, to improve linkage to, reten-
tion in, and reengagement in care.7,132
Evidence-based interventions to improve engagement in
care are limited and have been described elsewhere.133-135 Brief
case management improved rates of linkage to care (within 6
months) and is recommended after diagnosis (evidence rating
AIa).136,137 Linkage to and retention in care may be enhanced
through expedited care entry and rapid ART initiation within days
of diagnosis,19,20 and adequately powered intervention trials
using this approach are planned. Patient navigation and intensive
outreach can improve retention in care138,139 but are most appro-
priate for a subset of patients at greatest risk because of the high
resource requirements and cost. A patient navigation interven-
tion with or without financial incentives improved engagement in
care following inpatient hospitalization but did not show sus-
tained improvement of viral suppression.140 Integration of
directly observed ART in methadone maintenance programs (evi-
dence rating BIa)141 and as a treatment strategy among persons
with substance use disorders (evidence rating BIa)142 and those
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who are incarcerated or released to the community (evidence rat-
ing CIII)143 is recommended to enhance adherence and viral
suppression.134
Missedclinicvisitspredict clinical events, includingmortality,144
andrapid intervention followingamissedvisit is recommended(evi-
dence rating AIIa). Personal telephone and interactive short mes-
sageservice (SMS; text) reminders inadvanceof scheduledappoint-
mentsandshortly followingmissedappointments (eg,24-48hours)
improved retention inHIVmedical care across various settings and
are recommended (evidence rating AIa).145,146
Viral loadmeasurement is not recommended for screening for
ARTadherence; clinicians shoulddirectly screen for adherence, ide-
ally to identify and intervene in ART nonadherence prior to viral re-
bound. Adherence monitoring using patients’ self-reports via vali-
dated adherence instruments and pharmacy refill data are
recommended (evidence ratingAIIa).134 Self-reports typically over-
estimateadherence,butdegreeof self-reportednonadherencepre-
dicts virologic failure and evenmortality.147,148 Other interventions
that improved ART adherence and some that improved viral sup-
pression are described elsewhere.134,135
Active substanceuse is associatedwithpooradherence.Opioid
substitution therapy for opioid-dependent patients improves
retention in care and is recommended (evidence rating AIIa).149
Depression is associated with poor adherence, and routine screen-
ing for depression is recommended (evidence rating AIII).110,134
Depression treatment improved ART adherence150 and HIV
outcomes151; however, 3 US-based randomized clinical trials of anti-
depressant treatment showed no effect on ART adherence.152-154
More intensive behavioral interventions integrating depression
and adherence counseling showed improvement in both
outcomes.155-157
Prevention
Recommendations for preventionofHIV infection are summarized
in Box 7. Use of ARVs has expanded beyond treatment of HIV in-
fection. ART for pregnant women can eliminate mother-to-child
transmission.158-160 With “treatment as prevention,” heterosexual
transmission canbeprevented if theHIV-infectedpartner achieves
viral suppression.4,161-163 An increasingly robust observational data
set suggests similarbenefit fordecreasing transmissionamongmen
whohave sexwithmen.5,164Data are not available for personswho
injectdrugs,but theassumption is that therewouldbeasimilarben-
efit. In addition, ARVs are effective as PrEP in reducing the risk of
HIV acquisition.
Treatment as Prevention
ART is recommended for all HIV-infected individuals with detect-
able viremia, not onlybecauseof individual healthbenefits but also
because of the reduced infectiousness of ART-treated individuals
with virologic suppression (evidence rating AIa).
Preexposure Prophylaxis
PrEP is aneffectiveHIVprevention tool that is part of a “prevention
package” forHIV-seronegativepersons at risk.Detailed sexual, sub-
stanceuse,andmedicalhistoriesare important fordecidingwhether
toprovidePrEP. Individualswhoarecandidates forPrEP includeany-
one fromapopulationwith anHIV incidenceof at least 2%per year
(evidence rating AIa) or HIV-seronegative partners of HIV-infected
personswhodonot have viral suppression. Guidelines for identify-
ing candidates for PrEP have been published.165-167 Of note, PrEP
does not prevent other sexually transmitted infections.
Daily TDF/emtricitabine with high adherence is highly effec-
tive for HIV prevention and is the recommended regimen (evi-
dence rating AIa).168-173 Intermittent, event-driven PrEPwas effec-
tive in a single study among a highly sexually active population.174
There isevidencethat4ormoredosesofPrEPperweekconferspro-
tectionagainstHIV infection throughanal sex169,175,176; in theevent-
driven study, the average number of doses taken was 4 per week,
which may account for the observed success of this strategy. Less
thandailydosingmaynotbeeffective for vaginal exposuresaccord-
ing to pharmacologic modeling data.177,178 Therefore, daily dosing
ofTDF/emtricitabine forPrEP is recommended(evidenceratingAIa),
and there are currently insufficient data to recommend intermit-
tent dosing.
In a single randomized clinical trial of TDFalone inpersonswho
inject drugs, 49%were protected against HIV infection overall but
74%were protected when drug was detected.179 Data on efficacy
of PrEP for transgender individuals are limited.169,180Data ondrug-
drug interactions between PrEP agents and cross-sex hormone
therapy and data on PrEP in transgender women do not exist and
are needed.
Box 6. Recommendations for Engagement in Care
and ART Adherencea
• Routine opt-out HIV screening is recommended in primary
medical care settings and emergency departments and for all
pregnant women (evidence rating AIII).
• Systematic monitoring of time to care linkage following initial
HIV diagnosis, retention in care, ART adherence, and rates
of viral suppression is recommended in all care settings
(evidence rating AIIa).
• Brief case management is recommended after HIV diagnosis
(evidence rating AIa).
• Rapid intervention following amissed clinic visit is recommended
(evidence rating AIIa).
• Integration of directly observed ART in methadonemaintenance
programs (evidence rating BIa) and as a treatment strategy
among persons with substance use disorders (evidence
rating BIa) and those who are incarcerated or released to the
community (evidence rating CIII) is recommended to enhance
adherence and viral suppression.
• Personal telephone and interactive text reminders in advance
of scheduled appointments and shortly followingmissed
appointments (eg, 24-48 hours) are recommended
(evidence rating AIa).
• Adherencemonitoring using patients’ self-reports by validated
adherence instruments and pharmacy refill data are
recommended (evidence rating AIIa).
• Opioid substitution therapy for opioid-dependent patients is
recommended (evidence rating AIIa).
• Routine screening for depression is recommended (evidence
rating AIII).
Abbreviation: ART, antiretroviral therapy.
a See text for essential details and cautions. All recomendations are new
or evidence ratings have changed substantially since the 2014 report.
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Becauseof theTDFcomponent, TDF-basedPrEP is not recom-
mended for those with osteopenia or osteoporosis (evidence rat-
ing AIII) or a creatinine clearance rate of less than 60mL/min (evi-
dence ratingAIIa)andshouldbeusedwithcaution in thosewithHBV
coinfection (out of concern for flares of hepatitis or hepatic decom-
pensation on cessation of treatment, particularly among patients
with cirrhosis) (evidence rating BIIa).
Approximately9%168 to 14%175of individuals receivingPrEPex-
perience gastrointestinal adverse effects, which are often self-
limited. Glomerular dysfunctionwith decreases in creatinine clear-
ance rate may occur181,182 and to date have been reversible with
discontinuation. Rechallenge with the PrEP regimen is often
possible.183,184 Tenofovir disoproxil fumarate–basedPrEPhasbeen
associatedwitha1%to1.5%lossofbonemineraldensityat48weeks
at the hip and spine,185-187 with return to baseline on discontinua-
tion of PrEP.188 Individuals at high risk of osteopenia or osteoporo-
sis should carefully weigh risks and benefits of PrEP.
HIV testing, preferably with a combination antigen-antibody
assay (evidence rating AIII), serum creatinine, estimated creati-
nine clearance, and hepatitis B surface antigen must be per-
formed prior to initiation of PrEP (evidence rating AIa). For high-
incidence populations, especially those with a history of recent
exposure, an HIV RNA assay may be helpful in excluding acute
HIV infection prior to PrEP. Oral, rectal, urine, and vaginal sexually
transmitted infection screening, including serologic testing for
syphilis and nucleic acid amplification testing for chlamydia and
gonorrhea, is recommended as appropriate, and any sexually
transmitted infections should be treated (evidence rating BIII).
Vaccination against hepatitis A and hepatitis B viruses is recom-
mended for those who are not immune (evidence rating AIII).
Vaccination is recommended for women aged 13 to 26 years and
for men aged 13 to 21 years who have not been vaccinated previ-
ously or who have not completed the 3-dose series. Men aged 22
to 26 years may be vaccinated (evidence rating AIa).189 Women
should be screened for pregnancy.
Intervals of follow-up should be no longer than every 3months
to allow for HIV testing (by antigen-antibody assay unless symp-
toms or signs of acute HIV infection are present, in which case HIV
Box 7. Recommendations for Prevention of HIV Infectiona
• ART is recommended for all HIV-infected individuals with
detectable viremia, not only because of individual health benefits
but also because of the reduced infectiousness of individuals
achieving virologic suppression with ART (evidence rating AIa).
• PrEP should be considered for anyone from a population whose
HIV incidence is at least 2% per year (evidence rating AIa)
or HIV-seronegative partners of HIV-infected persons who do not
have viral suppression.
• Daily (rather than intermittent) TDF/emtricitabine is the
recommended PrEP regimen (evidence rating AIa).
• Tenofovir disoproxil fumarate–based PrEP is not recommended for
individuals with osteopenia or osteoporosis (evidence rating AIII)
or a creatinine clearance rate of less than 60mL/min (evidence
rating AIIa) and should be used with caution in patients with
chronic hepatitis B virus infection (evidence rating BIIa).
• Tenofovir alafenamide/emtricitabine is not recommended for PrEP
until effectiveness has been demonstrated in clinical trials
(evidence rating AIII). Use of non–TDF-containing PrEP or
augmentation of TDF/emtricitabine PrEP with other agents is not
recommended (evidence rating AIII).
• HIV testing, preferably with a combination antigen-antibody assay
(AIII), serum creatinine, and estimated creatinine clearance is
recommended prior to initiation of PrEP (evidence rating AIa).
• Oral, rectal, urine, and vaginal sexually transmitted infection
screening, including for syphilis, chlamydia, and gonorrhea,
is recommended as appropriate, and any sexually transmitted
infections should be treated (evidence rating BIII).
• Vaccination against hepatitis A and hepatitis B for those who are
not immune and human papillomavirus vaccination are recom-
mended (evidence rating AIII).
• Vaccination is recommended for women aged 13 to 26 years and
for men aged 13 to 21 years who have not been vaccinated
previously or who have not completed the 3-dose series.
Men aged 22 to 26 years may be vaccinated
(evidence rating AIa).
• Follow-up at intervals of no longer than every 3months is
recommended to allow for HIV testing (evidence rating AIII)
and sexually transmitted infection screening (evidence
rating BIIb).
• Creatinine assessment may be performed at least every 6months
(evidence rating AIII) and perhaps more frequently for some
patients (eg, aged >50 years, taking hypertension or diabetes
medications, or with estimated glomerular filtration rates at
threshold) (evidence rating CIII).
• Ongoing discussions about adherence are recommended,
especially in the absence of proven PrEP adherence interventions
(evidence rating CIII).
• Patients taking PrEP who have suspected HIV infection, on clinical
grounds or while awaiting HIV RNA confirmation of equivocal
screening test results, should have a boosted protease inhibitor
(ie, boosted darunavir) and and/or dolutegravir added to
TDF/emtricitabine pending HIV RNA and resistance testing results
(evidence rating AIII).
• Postexposure prophylaxis is recommended as soon as possible
after exposure without waiting for confirmation of HIV serostatus
of the source patient or results of HIV RNA or resistance testing
(evidence rating AIII).
• Tenofovir disoproxil fumarate/emtricitabine plus twice-daily
raltegravir or once-daily dolutegravir is recommendedby the
Centers forDiseaseControl andPrevention for postexposure
prophylaxis; TDF/emtricitabinewith cobicistat- or ritonavir-boosted
darunavir or TDF/emtricitabine/cobicistat/elvitegravir are reasonable
regimens (evidence ratingAIIb).
• Postexposure prophylaxis regimens should be continued for
28 days, and HIV serostatus should be reassessed at 4 to 6 weeks,
3 months, and 6months after exposure (evidence rating AIIb);
shorter follow-up (eg, 3 or 4months) may be possible with
a fourth-generation assay.
Abbreviations: ART, antiretroviral therapy; PrEP, preexposure prophylaxis;
TDF, tenofovir disoproxil fumarate.
a See text for essential details and cautions. All recommendations are new
or evidence ratings have changed substantially since the 2014 report.
Components separated with a slash (/) indicate that they are available as
coformulations.
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RNA testing should be ordered) (evidence rating AIII) and sexually
transmitted infection screening (evidence rating BIIb).190 Creati-
nine assessment may be performed at least every 6 months (evi-
dence rating AIII) and perhaps more frequently for some patients
(eg, those aged >50 years, taking hypertension or diabetesmedica-
tions, or with eGFRs at threshold)181,191 (evidence rating CIII).
Adherence is crucial to the success of PrEP, and ongoing discus-
sions about adherence are important, especially in the absence of
proven PrEP adherence interventions (evidence rating CIII).
AnypositiveHIVscreeningtest result forapatient receivingPrEP
should prompt immediate confirmatory testing for HIV RNA and
genotype testing if confirmed. Patients using PrEP who have sus-
pectedHIV infection, on clinical groundsorwhile awaitingHIVRNA
confirmation of equivocal screening test results, should have a
boostedPI (ie,boosteddarunavir) and/ordolutegraviraddedtoTDF/
emtricitabine pending HIV RNA and resistance testing results (evi-
dence rating AIII). Resistance has been observed rarely and most
commonly (although not universally) when PrEP with TDF/
emtricitabine is initiatedduringoccult acuteHIV infectionandmost
commonly with M184V/I alone. Transmission of multiclass-
resistant HIV despite daily PrEP use was recently reported in a gay
man in North America.192
Currently, there are no human data to support the efficacy of
otheroralHIVARVs forPrEP.Despiteanattractive safetyprofile and
a promising result in an animal study,193 tenofovir diphosphate lev-
els in genital compartment tissues were low following administra-
tion of a single dose of TAF.194 Tenofovir alafenamide/emtricita-
bine is not recommended for PrEP until effectiveness has been
demonstrated in clinical trials (evidence rating AIII). Use of non–
TDF-containing PrEP or augmentation of TDF/emtricitabine PrEP
with other agents is not recommended (evidence rating AIII).
Postexposure Prophylaxis
PEP is an emergency intervention designed to abort HIV acquisi-
tion in the event of occupational (ie, needlestick or mucous mem-
brane splash) or nonoccupational (ie, sexual or injecting drug use)
exposure to HIV-infected blood or potentially infectious bodily flu-
ids. A case-control studyestimated anefficacy rate of81% for zido-
vudine monoprophylaxis.167,195 Efficacy is likely higher for combi-
nation PEP, but no data exist.195 PEP is recommended as soon as
possible without waiting for confirmation of HIV serostatus of the
source patient or results of HIV RNA or resistance testing (evi-
dence rating AIII). The majority of guidelines recommend PEP ini-
tiation only within 72 hours of exposure.196 Baseline assessments
should includeHIVantibodytesting(ideally, acombinationantibody/
antigen test), sexually transmitted infection testing,pregnancy test-
ing for women of childbearing potential, and hepatitis B and C se-
rologies.TheCenters forDiseaseControlandPreventionrecommend
TDF/emtricitabine plus twice-daily raltegravir or once-daily
dolutegravir196; TDF/emtricitabinewith boosted darunavir or TDF/
emtricitabine/cobicistat/elvitegravirare reasonablealternatives (evi-
dence rating AIIb). PEP should be continued for 28 days, and HIV
serostatus shouldbe reassessed4weeks to6weeks, 3months, and
6monthsafterexposure (evidence ratingAIIb), althoughshorter se-
rologic follow-up (eg, at 3 or 4 months) may be possible if using a
fourth-generation assay. Persons who repeatedly seek PEP should
be considered for PrEP, as daily PrEPmay bemore protective than
repeated episodes of PEP.165
Future Directions
Up to96%ofpatientswho remain in care and receiveARThaveun-
detectableplasmaHIVRNA levels.22-26Newer therapiesmustbepo-
tent, simple, safe, and tolerable to be competitive or fulfill a spe-
cific niche, such as activity against multidrug-resistant variants or
availability as long-acting formulations.
Long-actingARTmayallowpatientswhohavedifficultywithdaily
oral therapy to maintain suppression, allow for directly observed
therapy in clinical or nontraditional settings, and provide treatment
duringperiodswhenoral therapy isdifficult (eg, surgery, travel,men-
tal illness,or transitions fromhospitalizationtooutpatientcare).With
acombinationofananoformulatedNNRTI(long-actingrilpivirine)and
an InSTI (injectable cabotegravir), virologic suppression was main-
tained for 32weekswhengiven intramuscularly once every4weeks
or8weeks.197Other long-actingtherapiesbeingevaluatedincludeim-
plantablesustained-releaseplatforms,nanoparticles, viral vectorde-
livery, monoclonal antibodies, and longer-acting oral therapy.198,199
Long-actingARThas thepotential to reducetheneedfordailyadher-
encetooraltherapy,butsuboptimaladherencetolong-actingARTmay
also have adverse consequences, as delayed or missed treatment
could mean prolonged periods with subtherapeutic ART levels, in-
creasing the risk of suboptimal drug concentrations. Therefore, pa-
tients at high risk of suboptimal adherencemay require comprehen-
sive treatment strategies to avoid delayed or missed doses.
Furthermore,whatmakes therapies long-acting (eg,peptides inviral
vectors,depotformulations,pharmacologicenhancers,etc)mayhave
their own drug interactions or long-term toxic effects, and further
evaluation is needed.
Injectable and other long-acting preparations for PrEP are cur-
rently in clinical development, including long-acting rilpivirine and
long-actingcabotegravir200andavaginal ringcontaining theNNRTI
dapivirine, which had a 27% to 30% efficacy in preventing HIV in-
fection among women in sub-Saharan Africa.201,202
Another investigational approach for both HIV treatment and
prevention is therapiesusingbroadlyneutralizingantibodies,which
may offer a new opportunity to clear replicating virus,203,204 clear
infected cells,205 and provide passive immunization to protect at-
risk individuals.206 The hurdles for these therapies include the re-
quirement for parenteral dosing, potential development of anti-
idiotypicantibodies, andpotential resistance tobroadlyneutralizing
antibodies in infected patients.
Ultimately, if a cure for HIV infection could be developed, the
consequences of the infection (eg, chronic inflammation and
immune damage) and the need for ART would be eliminated. An
ideal cure would also eliminate the need for routine monitoring
and the stigma of having been infected with HIV. This target is a
high bar. There are 2 potential types of cure: (1) a functional cure,
in which an infected person controls infection without therapy
and without the consequences of HIV-related immune activation
or inflammation and (2) an eradication cure, in which all
replication-competent virus is purged from an infected individual.
The current search for a cure is both aspirational and necessary to
build the foundation of knowledge to design and test cure strate-
gies. Current strategies include reactivating latent virus and purg-
ing it from reservoirs (ie, “shock and kill”),207 gene therapy
(knocking in protective genes such as fusion peptide or silencing
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RNA208-210 or knocking out susceptible genes such as CCR5211 or
the provirus), and immune enhancement (eg, therapeutic vac-
cines and immune checkpoint modulators).212 Similar to ART, a
successful cure strategy may require more than 1 agent delivered
simultaneously or in a series. To gain widespread use, functional
or eradication cure strategies must have limited risk, given the
safety and effectiveness of current ART.
In addition, to further maximize the enormous potential ben-
efit ofARTon theglobalHIVepidemic, newer, less toxic drugsmust
be made available in all countries; health care systems must be
strengthened, including increasedfocusonearlydiagnosisandtimely
linkage to and retention in care; and routine viral load monitoring
must be implemented to identify treatment failures early andmini-
mize the emergence of resistance. Widespread implementation of
early diagnosis and treatment requires a global effort to reduce
stigmaanddiscriminationand toensure thatHIV-infected individu-
als seek help without restrictions.
Conclusions
Antiretroviral agents remain the cornerstone of HIV treatment and
prevention. All HIV-infected individuals with detectable plasma vi-
rus should receive treatment, with recommended initial regimens
consistingofan InSTIplus2NRTIs.PrEPshouldbeconsideredaspart
of anHIV prevention strategy for at-risk individuals.When used ef-
fectively, currently available ARVs can sustain HIV suppression and
canpreventnewHIV infection.With these treatment regimens, sur-
vival rates among HIV-infected adults who are retained in care can
approach those of uninfected adults.
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